OncoHost

Precision Diagnostics and Predictive Biomarker Development

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in April 2017 by Yuval Shaked, OncoHost operates with 11–50 employees. The company has raised $53.4 million across 8 funding rounds from 7 investors, with OurCrowd participating in multiple rounds. A significant milestone for OncoHost was receiving a grant from the EIC Transition Programme in May 2025 to advance precision oncology for immunotherapy patients.

Business overview

OncoHost is a technology company focused on transforming precision medicine to improve patient outcomes in clinical oncology. The company addresses treatment resistance by understanding a patient's unique response to therapy. Its core product, the PROphet platform, integrates bioinformatics, system biology, proteomic pattern recognition, and machine learning to provide clinicians with actionable insights, optimize therapy choices, and enhance understanding of personalized cancer dynamics. OncoHost operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Pharma & Medical Biotechnology, serving markets in Israel, the United Kingdom, and the United States.

Strategic signal

In March 2026, OncoHost was recognized with the 2026 Artificial Intelligence Excellence Award in the Health category. This award highlights the company's leadership in leveraging AI and proteomic analysis for clinical decision-making in oncology, signaling strong validation of its technological approach and potential for continued innovation in personalized cancer care.

Company Intelligence Q&A

What is OncoHost's primary focus?
OncoHost is a technology company dedicated to transforming precision medicine to improve patient outcomes by understanding individual responses to cancer therapies and overcoming treatment resistance.
What is the PROphet platform?
The PROphet platform is OncoHost's core technology, which combines bioinformatics, system biology, proteomic pattern recognition, and machine learning to provide clinicians with actionable insights, optimal therapy choices, and a better understanding of personalized cancer dynamics.
When was OncoHost founded and by whom?
OncoHost was founded in April 2017 by Yuval Shaked.
Has OncoHost received any recent grants?
In May 2025, OncoHost was awarded a grant from the EIC Transition Programme to advance precision oncology for patients receiving immunotherapy.
What recent recognition has OncoHost received?
In March 2026, OncoHost won the 2026 Artificial Intelligence Excellence Award in the Health category, recognizing its AI-driven precision oncology solutions.

External links